Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TK1 | P04183 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | AMD1 | P17707 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982748 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL439797 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL529559 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL27054384 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL5982753 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| Phosphoric Acid SCHEMBL16871802 | 0.96 | ADORA3 (0.50) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL443066 | 0.88 | TK1 (0.46) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL27053980 | 0.87 | AMD1 (0.43) | ADORA3ADORA2AAMD1 | |
| SCHEMBL5982026 | 0.87 | LMNA (0.45) | ADORA3ADORA2ADNMT1ADRB1LMNA | |
| SCHEMBL5982032 | 0.87 | LMNA (0.45) | ADORA3ADORA2ADNMT1ADRB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313888-A1 | ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| US-20220267841-A1 | ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. | 2022-08-25 | — | — | US | claimed |
| EP-4043584-A1 | IMPROVED ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | Twinstrand Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-3387152-A1 | IMPROVED ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | Twinstrand Biosciences, Inc. (US) | 2018-10-17 | — | — | EP | claimed |
| US-20170211140-A1 | ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. | 2017-07-27 | — | — | US | claimed |
| WO-2017100441-A1 | IMPROVED ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2012016145-A2 | MITOCHONDRIAL APOPTOSIS-INDUCED INFLAMMATION | CEDARS-SINAI MEDICAL CENTER (US) | 2012-02-02 | — | — | WO | claimed |
| US-5962228-A | DNA SEQUENCING USING PRIMER WALKING; REPEATED CYCLES OF NUCLEOTIDE IDENTIFICATION BY SELECTIVE EXTENSION AND PRIMER ADVANCEMENT ALONG TEMPLATE BY TEMPLATE MUTATION; PRIMERS HAVE COMPLEXITY-REDUCING NUCLEOTIDES | LYNX THERAPEUTICS, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-4741514-A2 | METHODS AND REAGENTS FOR EFFICIENT GENOTYPING OF LARGE NUMBERS OF SAMPLES VIA POOLING | Twinstrand Biosciences, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4450643-B1 | METHODS FOR TARGETED NUCLEIC ACID SEQUENCE ENRICHMENT WITH APPLICATIONS TO ERROR CORRECTED NUCLEIC ACID SEQUENCING | UNIV WASHINGTON (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-0876380-A1 | $i(IN SITU) PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5705333-A | Peptide-based nucleic acid mimics(PENAMS) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997042202-A1 | IN SITU PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND OLIGONUCLEOTIDE SYNTHESIS | HYBRIDON, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997042208-A1 | IN SITU PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE IN SYNTHESIS OF OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1996004000-A1 | PEPTIDE-BASED NUCLEIC ACID MIMICS (PENAMs) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | ADORA3 1197/4885ADORA2A 1754/4885DNMT1 274/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA3 4335/4885ADORA2A 3761/4885DNMT1 384/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | ADORA3 1734/4885ADORA2A 2575/4885DNMT1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.